Skip to search formSkip to main contentSkip to account menu

everolimus 5 MG Tablet for Oral Suspension [Afinitor]

Known as: Afinitor Disperz 5 MG Tablet for Oral Suspension, EVEROLIMUS 5 mg ORAL TABLET, FOR SUSPENSION [Afinitor Disperz] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
BACKGROUND Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine… 
2016
2016
Recent therapy options of gastro- intestinal neuroendocrine tumours. Neuroen- docrine tumors (NET) of gastroenteropancreatic (GEP… 
2016
2016
BackgroundmTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic… 
2015
2015
Everolimus (RAD001, Afinitor®) is an oral, selective mTOR inhibitor recently approved by the US-FDA in combination with… 
Review
2013
Review
2013
Oral everolimus (Afinitor®) in combination with exemestane is indicated for the treatment of hormone receptor-positive, human… 
Review
2013
Review
2013
Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), an intracellular protein kinase… 
2012
2012
The FDA approved a dissolvable form of everolimus (Afinitor Disperz) for the treatment of children with subependymal giant cell… 
2012
2012
In Austria, about 24% of women with initially diagnosed breast cancer (BC) have locally advanced and about 5% have metastatic… 
2009
2009
Introduction: The re-introduction of H-based therapy after progression on a lapatinib-containing regimen has not yet been… 
2009
2009
The purpose of this report was to evaluate efficacy and safety of second-line therapy with everolimus, an mTOR inhibitor, for the…